Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

<p>Submission based on positive results from Phase 3 PHALCON-NERD-301 in which vonoprazan 10 mg and 20 mg controlled heartburn symptoms through the entire 6 months of the study with a safety profile consistent with prior vonoprazan studies New drug application (NDA) seeks U.S. Food and Drug Administration (FDA) approval for vonoprazan as a daily treatment […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/phathom-pharmaceuticals-announces-vonoprazan-nda-submission-for-non-erosive-gerd/">Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>